NewsRoom Articles - Page 161 of 224

TuesdayJul 20, 2021 2:36 pm

Adequate Levels of Vitamin D May Benefit Breast Cancer Patients

A new study has found that patients with breast cancer who have sufficient levels of vitamin D have better outcomes in the long term. Prof. Song Yao, who is the lead author of the study, suggests that maintaining adequate levels of vitamin D at the time of diagnosis and even after treatment may benefit breast cancer patients. The study’s results, which were presented at the American Society of Clinical Oncology’s virtual annual meeting, included findings that show that Black women had the lowest levels of vitamin D, which may explain why they had poorer outcomes after being diagnosed with breast…

TuesdayJul 20, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory…

MondayJul 19, 2021 1:30 pm

Study Finds Regular Physical Activity Boosts Brain Health in Growing Children

A recent study conducted by researchers from Boston Children’s Hospital has found that exercise assists in the organization of developing brains in growing children. The study discovered that physical activity was linked to more flexible, strong and efficiently organized brain networks. Dr. Caterina Stamoulis, who is the study’s lead, conducted an analysis of brain imaging data collected from an estimated 6,000 children between the ages of nine and ten. Stamoulis, who is also the head of the Boston Children’s Computational Neuroscience Laboratory, explained that the physical activity children engaged in didn’t matter as long as they were active. She conducted…

MondayJul 19, 2021 11:22 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

FridayJul 16, 2021 2:05 pm

Sleep Apnea, Genetic Predisposition Linked to Severe Coronavirus Infection

A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study, which was reported in the BMJ journals, noted that moderate to acute sleep apnea predisposes individuals to acute coronavirus. Other coronavirus risk factors include older age, diabetes and a high body mass index. The researchers used FinnGen data for their study, which was backed by the Center of Excellence in Complex Disease Genetics. The researchers linked data obtained from the Finland National Infectious Disease Register on coronavirus…

FridayJul 16, 2021 1:58 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

FridayJul 16, 2021 9:30 am

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection. A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting. As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space. As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered…

ThursdayJul 15, 2021 1:08 pm

Report Finds That Use of Remote Health Has Grown Significantly

A recent survey conducted in the second quarter of this year by Parks Associates has found that more than one-half of broadband households own an internet-enabled fitness or health device that records biometric data, with another two-thirds revealing that they have undergone remote health consultation. The survey, which involved 5,000 broadband households in the United States was conducted by Parks Associates, a market research and consulting firm that specializes in emerging consumer technology products. Parks Associates senior analyst Kristen Hanich stated that the overall familiarity with telehealth had assisted in driving the connected health device market. Hanich noted that there…

WednesdayJul 14, 2021 11:43 am

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developer Piezo Motion's technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatments Merger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced that it has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric…